Vitamin D Boosts Antimicrobial Peptide Cathelicidin to Improve Eczema and Fight Skin Infections
A systematic review of 68 studies found that vitamin D supplementation (1,000-2,000 IU/day for 1-3 months) increases cathelicidin antimicrobial peptide expression and reduces Staphylococcus aureus colonization and eczema severity in people with vitamin D deficiency.
Quick Facts
What This Study Found
The systematic review of 68 peer-reviewed papers established two key findings:
1. Cathelicidin plays a dual role in atopic dermatitis — it contributes to skin barrier function and has direct anti-Staphylococcus aureus activity. Reduced cathelicidin expression in AD patients weakens both defenses.
2. Vitamin D supplementation at 1,000-2,000 IU/day for 1-3 months increases cathelicidin expression and reduces S. aureus abundance and AD severity — but only in individuals with low serum vitamin D (deficiency/insufficiency). There was no evidence supporting supplementation in people with sufficient vitamin D levels.
Key Numbers
How They Did This
Systematic literature search following established protocols, with 68 peer-reviewed papers accepted for inclusion. Studies were critically appraised and synthesized in a narrative analysis. The review examined three interconnected relationships: cathelicidin's role in skin barrier function, cathelicidin's anti-S. aureus activity, and vitamin D's ability to upregulate cathelicidin expression in the context of atopic dermatitis.
Why This Research Matters
Atopic dermatitis affects up to 20% of children and 10% of adults, and S. aureus skin infections are a major complication causing disease flares. Current treatment relies on topical steroids and immunosuppressants, which have side effects with long-term use. The cathelicidin-vitamin D connection offers a natural, low-cost intervention: simply correcting vitamin D deficiency can boost the body's own antimicrobial peptide defense, reducing infections and eczema severity. This represents a mechanistic, nutrition-based approach to managing a common chronic condition.
The Bigger Picture
This review connects three major areas: antimicrobial peptide biology, nutritional medicine, and dermatology. The vitamin D-cathelicidin axis is one of the best-characterized examples of how a nutrient directly regulates antimicrobial peptide expression — vitamin D literally turns on the cathelicidin gene. Understanding this mechanism has implications beyond eczema: it may explain why vitamin D deficiency is associated with increased susceptibility to respiratory infections, wound healing problems, and other conditions where antimicrobial peptides play protective roles.
What This Study Doesn't Tell Us
The review is a narrative synthesis rather than a formal meta-analysis, limiting quantitative conclusions. Most vitamin D supplementation studies in AD are small and heterogeneous in design. The benefit is limited to vitamin D-deficient/insufficient individuals, and many studies didn't stratify by baseline vitamin D status. Optimal dosing and duration beyond the identified 1,000-2,000 IU/day for 1-3 months range are not established. The causal chain (low VD → low cathelicidin → worse AD) is well-supported mechanistically but not definitively proven in clinical trials.
Questions This Raises
- ?Would higher vitamin D doses produce greater cathelicidin induction and better eczema outcomes in severely deficient patients?
- ?Could topical vitamin D application directly boost cathelicidin in the skin more effectively than oral supplementation?
- ?Does the vitamin D-cathelicidin mechanism explain the seasonal variation in eczema severity?
Trust & Context
- Key Stat:
- 1,000-2,000 IU/day vitamin D boosts cathelicidin In VD-deficient eczema patients, supplementation for 1-3 months increased antimicrobial peptide expression, reduced S. aureus, and improved disease severity
- Evidence Grade:
- This is a systematic review synthesizing 68 peer-reviewed studies with critical appraisal. While not a formal meta-analysis, the consistent findings across multiple study types support the vitamin D-cathelicidin-AD connection. The evidence for supplementation benefits is strongest for VD-deficient populations.
- Study Age:
- Published in 2025, this is a current review capturing the latest evidence on the vitamin D-cathelicidin axis in atopic dermatitis, including recent clinical trial data.
- Original Title:
- Cathelicidin expression in the pathogenesis of atopic dermatitis and the therapeutic potential of vitamin D.
- Published In:
- Nutrition research (New York, N.Y.), 139, 113-123 (2025)
- Authors:
- Connell, Tess, Seidler, Karin(2), Neil, James
- Database ID:
- RPEP-10528
Evidence Hierarchy
Frequently Asked Questions
What is cathelicidin and how does it protect the skin?
Cathelicidin (also called LL-37 in its active form) is an antimicrobial peptide produced by skin cells as part of the innate immune system. It directly kills bacteria like Staphylococcus aureus by disrupting their cell membranes, and also helps maintain the skin barrier. In eczema patients, cathelicidin levels are often low, leaving the skin vulnerable to infections and barrier breakdown.
Should I take vitamin D for my eczema?
According to this review, vitamin D supplementation (1,000-2,000 IU/day for 1-3 months) may improve eczema if your vitamin D levels are low. Ask your doctor to check your serum vitamin D level. If you're deficient or insufficient, supplementation could boost your skin's natural antimicrobial peptide defense and reduce eczema severity. However, if your vitamin D is already at healthy levels, supplementation is unlikely to provide additional benefit for eczema.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-10528APA
Connell, Tess; Seidler, Karin; Neil, James. (2025). Cathelicidin expression in the pathogenesis of atopic dermatitis and the therapeutic potential of vitamin D.. Nutrition research (New York, N.Y.), 139, 113-123. https://doi.org/10.1016/j.nutres.2025.05.006
MLA
Connell, Tess, et al. "Cathelicidin expression in the pathogenesis of atopic dermatitis and the therapeutic potential of vitamin D.." Nutrition research (New York, 2025. https://doi.org/10.1016/j.nutres.2025.05.006
RethinkPeptides
RethinkPeptides Research Database. "Cathelicidin expression in the pathogenesis of atopic dermat..." RPEP-10528. Retrieved from https://rethinkpeptides.com/research/connell-2025-cathelicidin-expression-in-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.